NCT06045065Completed
Preclinical Brain Tumor Models
Establishment of Pre-clinical Stem Line and Tumoroid Models of Brain Tumors
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Background: Primary or secondary brain tumors (metastases) remain associated with a very poor prognosis linked to significant therapeutic resistance. Thus, glioblastoma, which is the most common and aggressive primary brain tumor in adults, is associated with inevitable relapses within 7 to 10 months and median survival of approximately 12 to 14 months. At the same time, brain metastases are increasingly increasing following better systemic control of other metastatic sites and improvement in detection methods. However, they remain resistant to the latest therapeutic innovations such as immunotherapies or targeted therapies. In this context, innovative strategies are necessary to identify new therapeutic targets and implement new treatments to overcome resistance phenomena in the clinic. Objective: Our goal will be to generate tumoroids and stem-like cell lines (PDX) from patient tumor samples. Methods: We will establish tumor tumoroids and stem cell lines from patient samples. These preclinical models will allow us to test a large number of drugs, quickly and efficiently thanks to models as close as possible to patient tumors and limiting the use of animal models (3R). Overall, this project should enable major advances in the treatment of glioblastoma and brain metastases and enable the rapid testing of new molecules in clinical trials thanks to the homology of our models with our patients' diseases.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 13 Sept 2023
- Start date
- 2 Jan 2022
- Primary completion date
- 25 Nov 2024
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Diseases
- Glioblastoma
- NCT number
- NCT06045065
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 2 Jan 2022 to the primary completion date, 25 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- unresectable tumor
Who the study is looking for
- Adult patients
- Brain tumor neuro-imaging
- Eligible for neurosurgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille | Marseille | France | Unknown status |
The registry text, word for word
This page is information, not medical advice. Discuss any trial with your doctor.